**ANZMUSC Trial of the Year Award 2023**

The Australia and New Zealand Musculoskeletal (ANZMUSC) Clinical Trials Network aims to optimise musculoskeletal health through high quality, collaborative clinical research. ANZMUSC established the Trial of the Year Award in 2022 to recognise, encourage, and celebrate members who have conducted a high-quality trial in the field of musculoskeletal health.

**Award Guidelines**

Trials considered for the ANZMUSC Trial of the Year Award will be collaboratively developed, multicentre, investigator-driven, randomised controlled trials that were designed to improve patient-centred outcomes or healthcare delivery in the field of musculoskeletal health.

The trial must have been designed and led by a network or investigator group that is a current Member of ANZMUSC (Full or Associate) and the primary results[[1]](#footnote-1) of the trial must have been published in the 2022 calendar year (electronically or in print) in the English language (published in any country). This includes research papers that are only available online. For papers that are “epub ahead of print” the date of first online publication of the final version will specify the publication year. A paper may only be nominated once for this award and will not be considered for multiple years by using different dates associated with epub vs. print formats. Nominations are due on September 8, 2023.

The ANZMUSC Scientific Advisory Committee (SAC) will review all nominations. The panel reserves the right to not make an award during a calendar year. The panel also reserves the right to award a runner-up where a nomination is deemed worthy. The panel will judge the trial that is the best demonstration of the following standards[[2]](#footnote-2):

* **It addressed a critical gap in the evidence or a significant innovation in musculoskeletal healthcare delivery.**
* **The quality of the research design, conduct and analysis were outstanding.**
* **There is a high likelihood that findings from the trial will significantly impact clinical practice and policy and improve outcomes for patients or musculoskeletal healthcare delivery.**

Any current ANZMUSC Member (Full or Associate) can nominate ONE trial for consideration. This can be a self-nomination or nomination of another ANZMUSC member.

**Announcement**

The applicant of the winning trial will be notified on the 25th of October 2023. The winning trial will be announced publicly and recognised at the ANZMUSC Scientific Meeting (24th & 25th October 2023). The winning investigator is not required to be present in-person to be recognised for the award during the 2023 ANZMUSC October Scientific Meeting, however, they may be invited to present a brief summary of their work (e.g. in-person, live virtually, recorded video).

**Prize**

The winner the Paper of the Year Award will be recognised through an ANZMUSC e-Newsletter and the ANZMUSC social media platforms. The first author will also receive complimentary registration at the face-to-face ANZMUSC Scientific Meeting in 2024 (or, in the case of inability to hold a face-to-face meeting that year, the next available face-to-face meeting) and a token prize.

**How to nominate a paper**

Current ANZMUSC members (Associate or Full) may self-nominate, or nominate another ANZMUSC member, for consideration by providing the following:

* **A completed nomination form signed by the applicant**
* **A PDF copy of the published paper and any supplementary materials.**

The nomination form can be found below.

**Nominations will close at 5:00pm AEST on Friday, September 8, 2023.** No further nominations will be accepted after the deadline.

Please submit the completed nomination form and the PDF copy of the publication and supplementary materials (with subject ‘ATTENTION: ANZMUSC Award Nomination’) to Helen Ramsay (admin@anzmusc.org).

|  |  |
| --- | --- |
| Scientific name of the trial |  |
| Short name of the trial |  |
| Please confirm that the nominated trial meets the following eligibility criteria *(please tick all that apply)* | [ ]  collaboratively developed[ ]  multicentre[ ]  investigator-driven[ ]  randomised controlled  |
| Name of the ANZMUSC Member that designed and led the trial |  |
| Name of the coordinating centre that managed the trial’s conduct |  |
| Name of the Chief Investigator |  |
| Email |  |
| Phone |  |
| Citation of the publication in which the primary results were reported (include weblink if available) |  |
| Date trial results published (electronic or print) |  |
| Is there a statistical plan published? If so, please provide the web address. |  |
| Did this trial receive funding from the NHMRC? If so, please provide the amount and the NHMRC Funding ID number. |  |
| Did this trial receive funding from the Commonwealth, other than the NHMRC? If so, please provide the amount and identifier (where appropriate). |  |
| Did this trial involve any formal collaboration with a commercial entity? If so, please provide a brief summary of industry involvement. |  |
| Trial nominated by |   |
| Email |  |
| Phone |  |
| Signature |  |
| Date |  |

**Nomination Form**

|  |
| --- |
| **Summary of Paper** |
| Please provide a brief summary of the study and describe the paper according to each of the judging criteria below to warrant recognition as the Trial of the Year (minimum 11-pt font; maximum 500 words in total for all four categories of the peer summary): |
| **Summary:**  |
| **Addresses a critical gap in the evidence or a significant innovation in musculoskeletal healthcare delivery** |
| **The quality of the research design, conduct and analysis were outstanding** |
| **There is a high likelihood that findings from the trial will significantly impact clinical practice and policy and improve outcomes for patients or musculoskeletal healthcare delivery** |

|  |
| --- |
| **Lay Summary of Paper** |
| Please provide a lay summary describing the paper and how the results are likely to impact patients with musculoskeletal conditions and/or the delivery of musculoskeletal healthcare (minimum 11-pt font; maximum 300 words). This should be suitable for publication on the ANZMUSC website or social media. |
| **Lay Summary:** |

[ ]  A PDF copy of the published paper including any supplementary files is provided with this nomination form.

**DECLARATION FORM**

[ ]  I have read the award guidelines and believe that this trial is eligible to be considered for the ANZMUSC Trial of the Year Award.

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Signature Date

1. Primary results refers to the first publication reporting the analysis of trial’s primary endpoint as specified in the published protocol, statistical analysis plan or online trial registration profile. [↑](#footnote-ref-1)
2. The ANZMUSC Executive Committee will consider the recommendations of the judging panel/s in making decisions to announce the winning trials. ANZMUSC’s Executive Committee decision will be final. [↑](#footnote-ref-2)